FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCSL Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CSL.AX
CSL Limited Stock AnalysisComprehensive stock analysis for CSL Limited (CSL.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCSL.AX
CSL.AX
CSL Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CSL.AX
  1. Home
  2. Stocks
  3. CSL Limited

CSL Limited

🇦🇺CSL.AX•ASX

CSL Limited

🇦🇺CSL.AX•ASX

Your view on CSL.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About CSL Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Gordon Naylor DipCompSc
Headquarters
655 Elizabeth Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Gordon Naylor DipCompSc
Headquarters
655 Elizabeth Street, Melbourne, VIC, AU
Description

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China.

The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments.

This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties.

In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for CSL Limited. Starting points for CSL Limited: EPS -AUD 5.28, beta 0.08 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for CSL Limited. CSL Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for CSL Limited. Trailing twelve-month EPS for CSL Limited stands at -AUD 5.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate$0.00$4.14$6.43$6.87
Lowest estimate$0.00$4.14$6.28$6.47
Highest estimate$0.00$4.14$6.83$7.14
Number of analysts011313
A year ago$5.531$6.421−$5.471—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate$7.45B$8.51B$16.38B$16.89B
Lowest estimate$7.45B$8.51B$15.84B$16.55B
Highest estimate$7.45B$8.51B$16.64B$17.38B
Number of analysts111717
A year ago$3.64B$5.92B$16.04B—
Growth vs a year ago+104.6%+43.7%+2.1%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for CSL Limited. CSL Limited has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CSL.AX18 companies · 8 funds
Compare CSL.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ALNYAlnylam Pharmaceuticals, Inc.HealthcareBiotechnology$19.3B
INCYIncyte CorporationHealthcareBiotechnology$23.4B
IONSIonis Pharmaceuticals, Inc.HealthcareBiotechnology$4.4B
MRNAModerna, Inc.HealthcareBiotechnology$78.9B
REGNRegeneron Pharmaceuticals, Inc.HealthcareBiotechnology$95.2B
RVMDRevolution Medicines, Inc.HealthcareBiotechnology$34.9B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$36.9M
PLRZPolyrizon Ltd.HealthcareNASDAQ$10.4M
PLURPluri Inc.HealthcareNASDAQ$10.1M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$244.5M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$66.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$2.2M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.4M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$46.7M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$210,578
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
ETFs holding CSL Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.16%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.21%
IEFAiShares Core MSCI EAFE ETF$188.8B in assets0.27%
EFAiShares MSCI EAFE ETF$75.5B in assets0.31%
EWAiShares MSCI Australia ETF$1.2B in assets4.75%
EPPiShares MSCI Pacific ex Japan ETF$2.2B in assets3.01%
GCOWPacer Global Cash Cows Dividend ETF$3.7B in assets1.44%
PBPHPortfolio Building Block World Pharma and Biotech Index ETF$1.4B in assets1.29%

Largest holders first, then the funds most concentrated in CSL.AX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold CSL Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for CSL Limited. Coverage tracks CSL Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of CSL Limited.

CSL.AX AnalysisFair
Past
3
Growth
4
Health
3
Profit
1
Value
1